Position in BCYC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,151,099
-$1,124,817 QoQ
Shares Held
463,599
+0.2% QoQ
Ownership
0.662%
of shares outstanding
% of Portfolio
1.27%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCYC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Birchview Capital, LP holds $86,547,277 across 48 Biotechnology names. BCYC ranks #15 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CMPX |
Compass Therapeutics, Inc.
|
1,465,867 | $7,754,436 | |
| 2 | STOK |
Stoke Therapeutics, Inc.
|
210,000 | $6,837,600 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
445,400 | $5,710,028 | |
| 4 | GPCR |
Structure Therapeutics Inc.
|
100,000 | $4,820,000 | |
| 5 | SLDB |
Solid Biosciences Inc.
|
625,980 | $4,507,056 | |
| 6 | PRTA |
Prothena Corp Public Ltd Co
|
449,019 | $4,364,464 | |
| 7 | ACAD |
Acadia Pharmaceuticals Inc
|
171,000 | $3,806,460 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
35,000 | $3,689,000 |
All Filings in BCYC
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,151,099 | 463,599 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,275,916 | 462,700 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,191,960 | 154,000 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||